https://buff.ly/3zdzsWj | @American Conference Institute is hosting their 4th Annual Series on Hatch-Waxman and BPCIA from October 8-24, 2024. This series is a virtual three-week program designed to provide new lawyers and executives for the life sciences industry with a solid foundation for understanding the essentials as well as the intricacies of Hatch-Waxman and BPCIA litigation and regulation. Save 10% with promo code D10-999-PM25 #HatchWaxman #BPCIA #ACIConferences
PM360 Magazine’s Post
More Relevant Posts
-
Sharing with you all an important Life Sciences Licensing and M&A update on recent decisions affecting commercially reasonable efforts definitions and post-patent expiration royalty obligations. Courtesy of my Goodwin colleagues Erin Svokos, Yasin Akbari, Alexandra Valenti, Shannyn Henke, Caroline Bullerjahn, Robert Frederickson, Sarah Stoiber, and Grant Michl. A must read! #goodwinlaw #legalupdate #lifesciences
Life Sciences Licensing and M&A Update: Catching Up on Recent Decisions Affecting Commercially Reasonable Efforts Definitions and Post-Patent Expiration Royalty Obligations | Insights & Resources | Goodwin
goodwinlaw.com
To view or add a comment, sign in
-
To the IP leaders in my network! It is now only 1 month until our free IP Collective Life Sciences Virtual Roundtable Discussions on May 22nd, and with our registration deadline looming, I would love to hear from those of you who are still not yet involved. If you are interested in discussing strategies to tackle some of the below challenges (and many more) with your peers, do reach out for some more information on LinkedIn, or alternatively email me at [email protected]. #IPCollective #IP #patents #UPC #litigation
To view or add a comment, sign in
-
RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:
Life sciences industry outlook - Fall 2023
To view or add a comment, sign in
-
While the eligibility requirement has always been there, the “framework” is new and impacts life sciences. Come to see what best practices Rolando and his panel have to share!
Rolando Medina will moderate the panel, “Best Practice - Traversing the New Patent Eligibility Framework,” at the Life Sciences Patent Network (LSPN) North America Spring Conference on May 8, 2024. #lspnspring #patent #lifesciences https://bit.ly/4bkOLuc
To view or add a comment, sign in
-
A not to be missed panel at the ABA Section of Intellectual Property Law annual conference in April. We will certainly dive deeper than practical drafting tips. With these panelists — Mark Lemley, Mark Stewart, Donna Meuth — we may be re-drafting the patent laws altogether. Lauren Mitchell will be moderating. #intellectualpropertylaw #patents #aba #dechert
Lauren Mitchell, Katherine A. Helm, Mark Lemley, Donna Meuth and Mark Stewart will address "Practical Drafting Tips Following Angen v, Sanofi" at the ABA-IPL Section Annual Meeting, April 17-19! ambar.org/iplspring
To view or add a comment, sign in
-
❗❗❗📚📚💡 💡New patent from Bristol Myers Squibb regarding #WEE1 CELMoD. If someone is truly interested in #WEE1 as a target, I highly recommend delving deeper into patent data. You can find a lot of interesting information that can help in building a robust SAR model for degraders. link to patent: https://lnkd.in/dnuFYNht #TPD #Targeted_Protein_Degradation #CRBN #WEE1 #molecular_Glue
To view or add a comment, sign in
-
Be prepared for negotiations in the New Year with the SRS Acquiom 2023 Life Sciences M&A Study—detailed analysis on milestones, deal terms, earnouts, disputes, and more. https://lnkd.in/g2NckJQN #LifeSciences #MergersAndAcquisitions #DealTerms
To view or add a comment, sign in
-
The battle to claim the earliest valid patent rights to CRISPR gene-editing technology has been fought around the world. In Australia, the most protracted dispute to date has focussed on priority rights of patent application AU2013335451, filed in October 2013 by South Korean biotech company, ToolGen Incorporated. This dispute has now come to an end, with ToolGen applying to amend the patent claims to overcome the Court’s earlier invalidity finding, including to correct an alleged “obvious mistake”. Read more: https://lnkd.in/gZzRtgXf #ipupdate #australiapatent #auslaw #patentprosecution #intellectualproperty #patentlaw #patent #australianpatent #pearceip #boutiquelawfirm
To view or add a comment, sign in
-
This year the Life Sciences Strategy Summit on IP & Exclusivity will have a Pre-Event SPC & PTE Forum on October 8! Discuss the updates and strategies concerning SPCs and PTEs, during this exclusice unique gathering of pharma and biotech regulatory, in-house counsel and private practice specialists. Update your life science exclusivity strategy for 2024 as you deep dive into these topics and more! - SPC Waiver Litigation Update and its Impact on the Generic and Innovator Landscape. - CJEU opinion for C-119/22 and C-149/22. - An update on the Unitary SPC proposal and how to update your European patenting strategy. - SPCs 101- What every patent practitioner needs to know about SPCs. Discover everything on offer during the pre-day and full event by viewing the agenda here: https://lnkd.in/g9ZCamBp #lifescience #SPC #regulatory #PTE #Litigation
To view or add a comment, sign in
-
Eden Research eyes more growth with label extensions and approvals - ICYMI @edenresearch #AIM #OTCQB #EDEN #EDNSF. Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive about the company's strong performance in the first half of the year, including a 65% jump in revenue to £1.89 million. Smith highlighted the key role of regulatory approvals in driving growth, with recent wins in markets like California, Spain, and Germany expanding Eden's reach. He emphasized that regulatory hurdles are both challenging and crucial, as they unlock significant new markets for products like Mevalone. Proactive: You've reported a big jump in first-half... http://ow.ly/9PAS105KbJS
To view or add a comment, sign in
4,288 followers